Research in Cancer and Brain Disorders disease

dailyeducation

Administrator
Staff member


IIT Kanpur's landmark research offers new hope in Cancer and Brain Disorders such as Alzheimer’s and Parkinson’s disease​





  • Ground-breaking findings on Receptor Proteins published in prestigious international journal, Science

January 5, 2024, Kanpur: The Indian Institute of Technology Kanpur (IITK) has achieved a breakthrough in biomedical research, with their study of G protein-coupled receptors (GPCRs) and chemokine receptor D6, shedding new light on the potential treatment of cancer and brain disorders such as Alzheimer’s disease, Parkinson’s disease and schizophrenia. The researchers visualized the atomic details of the receptors. The information from this major advance opens up the possibility of designing new drug-like molecules to modulate these receptors under disease conditions. This landmark work has been recognized internationally with its publication in the prestigious international journal, Science.


Research-team.jpg



Prof. S Ganesh, Director, IIT Kanpur said, "The path-breaking research opens the doors to a new era in targeted medicine that can deliver solutions for cancer and neurological conditions for millions across the world. These diseases, which cause immense suffering and economic burden, could see a new era of effective treatment developed based on these findings! The success of this research project is also a testament to our successful collaboration with scientists across the world. This project saw the team from IIT Kanpur working with researchers from Japan, the Republic of Korea, Spain, and Switzerland. Hearty Congratulations to Prof. Arun Shukla and team, who have been doing outstanding research in GPCRs Biology!"


This collaborative effort, involving international researchers not only enhances the understanding of complex diseases but also cements India's position as a leader in innovative biomedical research and highlights IIT Kanpur's commitment to addressing some of the most pressing health challenges.


G protein-coupled receptors (GPCRs) are like tiny antennas on the surface of brain cells which help them to communicate and play a key role in many brain functions. When these receptors don’t work properly, there are issues with communication between the brain cells leading to diseases like Alzheimer's and Parkinson's. This leads to the symptoms and progression seen in these diseases. Similarly, the chemokine receptor D6 functions in the immune system and is involved in the response to inflammation. In cancer, the receptor can influence the tumour environment, affecting how the cancer cells grow and spread.


The findings of the new research from IIT Kanpur will help in a greater understanding of the working of these receptors and lead to the development of new therapeutic approaches and targeted treatments for conditions such as Alzheimer's, which affects over 50 million people worldwide, and cancer, responsible for over 10 million deaths annually. The results of the research will now facilitate the development of new drug-like molecules that can be tested for their therapeutic potential in animal models.


The researchers used a high-tech method called cryogenic-electron microscopy (cryo-EM) to create detailed three-dimensional images of the receptors. This allowed them to study the 3D images of the receptors at the molecular level in great detail, helping to identify and design new drug-like molecules to correct problems with these receptors that cause disease conditions.


The research team from the Laboratory of GPCR Biology, IIT Kanpur included Prof. Arun K. Shukla, Department of Biological Sciences and Bioengineering and Principal Investigator GPCR Lab; Dr. Ramanuj Banerjee, Post-Doctoral Fellow; Dr. Manish Yadav, Post-Doctoral Fellow; Dr. Ashutosh Ranjan, Post-doctoral fellow, currently Faculty at Lucknow University; Jagannath Maharana, Ph.D. scholar now heading to the Max Planck Institute of Molecular Physiology as a post-doctoral fellow; Madhu Chaturvedi, Ph.D. scholar now heading to UCSF as a post-doctoral fellow; Parishmita Sarma, Ph.D. student; Vinay Singh, Project JRF, now headed to IMPRS on Cellular Biophysics, Frankfurt as a Ph.D. student; Sayanatan Saha, Project Research Fellow; and, Gargi Mahajan, Project Research Fellow.


The global collaboration saw researchers from across the world joining hands with IIT Kanpur to ensure the success of this research project. The research team included Fumia Sano, Wataru Shihoya and Osamu Nureki from Tokyo, Japan; Tomasz Stepniewski and Jana Selent from Barcelona, Spain; Mohamed Chami from Basel, Switzerland; and Longhan Duan and Ka Young Chung from Suwon, Republic of Korea.


The research work at IIT Kanpur was supported by the DBT/Wellcome Trust India Alliance, and Science and Engineering Research Board.


Reference: Molecular insights into atypical modes of β-arrestin interaction with seven transmembrane receptors. Maharana J, Sano F, Sarma P, Yadav M, Longhan D, Stepniewski TM, Chaturvedi M, Ranjan A, Singh V, Saha S, Mahajan G, Chami M, Shihoya W, Selent J, Chung KY, Banerjee R*, Nureki O* and Shukla AK*. Science, 2023.


About IIT Kanpur:


Indian Institute of Technology Kanpur was established in 1959 and declared to be to be an Institute of National Importance by the Government of India through an Act of Parliament. IIT Kanpur is best known for the highest standard of its education in science and engineering and seminal R&D contributions over the years. The institute has a sprawling lush green campus spread over 1055 acres with large pool of academic and research resources spanning across 19 departments, 25 centers and 3 interdisciplinary programs in engineering, science, design, humanities, and management disciplines with more than 570 full-time faculty members and approximately 9000 students.


For more information, visit .
fac-right-column-top-border.png


 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock